Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary

References

• Alexander, M. (2010). The new Jim Crow: Mass incarceration in the age of colorblindness. New York: New Press.
   Google Scholar
• Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011). Five year experience with collaborative care of opioid addicted patients using buprenorphine in primary care. Archives of Internal Medicine, 171(5), 425–431. doi:10.1001/archinternmed.2010.541
   Google Scholar
• American Society of Addiction Medicine. (2013). Drug testing: A white paper of the American Society of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine. Retrieved from: http://www.asam.org/docs/default-source/public-policy-statements/drug-testing-a-white-paper-by-asam.pdf
   Google Scholar
• Anstice, S., Strike, C. J., & Brands, B. (2009). Supervised methadone consumption: Client issues and stigma. Substance Use and Misuse, 44, 794–808. doi:10.1080/10826080802483936
   Google Scholar
• Ball, J. C., & Ross, A. (1991). The effectiveness of methadone maintenance treatment. New York: Springer-Verlag.
   Google Scholar
• Bao, Y.-P., Liu, Z. M., Epstein, D. H., Du, C., Shi, J., & Lu, L. (2009). A meta-analysis of retention in methadone maintenance by dose and dosing strategy. American Journal of Drug and Alcohol Abuse, 35, 28–33.
   Google Scholar
• Bentzley, B. S., Barth, K. S., Back, S. E., Aronson, G., & Book, S. W. (2015). Patient perspectives associated with intended duration of buprenorphine maintenance therapy. Journal of Substance Abuse Treatment, 56, 48–53. doi:10.1016/j.jsat.2015.04.002
   Google Scholar
• Biernacki, P. (1986). Pathways from heroin addiction: Recovery without treatment. Philadelphia: Temple University Press.
   Google Scholar
• Cohen, S. (1985). Visions of social control: Crime, punishment and classification. Cambridge: Polity.
   Google Scholar
• Corsi, K. F., Lehman, W. K., & Booth, R. E. (2009). The effect of methadone maintenance on positive outcomes for opiate injection drug users. Journal of Substance Abuse Treatment, 37(2), 120–126. doi:10.1016/j.jsat.2008.11.004
   Google Scholar
• Damon, W., Small, W., Anderson, S., Maher, L., Wood, E., Kerr, T., & McNeil, R. (2017). ‘Crisis’ and ‘everyday’ initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. Drug and Alcohol Review, 36(2), 253–260. doi:10.1111/dar.12411
   Google Scholar
• D'Aunno, T., Pollack, H. A., Frimpong, J. A., & Wuchiett, D. (2014). Evidence-based treatment for opioid disorders: A 23-year national study of methadone dose levels. Journal of Substance Abuse Treatment, 47(4), 245–250. doi:10.1016/j.jsat.2014.06.001
   Google Scholar
• Department of Alternative Sentencing. (n.d.). Probationer guidelines and contract. Reno, Nevada: Washoe County, Department of Alternative Sentencing. Retrieved from https://www.washoecounty.us/altsent/index.php
   Google Scholar
• Department of Vermont Health Access. (2015). Managed care entity, Vermont buprenorphine clinical practice guidelines. Waterbury, Vermont: Department of Health Access.
   Google Scholar
• Dole, V. P. (1994). Conversation with Vincent Dole. Addiction, 89(1), 23–29.
   Google Scholar
• Dole, V. P., & Nyswander, M. E. (1980). Methadone maintenance: A theoretical perspective. NIDA Research Monograph, 30, 256–261. Rockville, MD: National Institute on Drug Abuse.
   Google Scholar
• Fareed, A., Casarella, J., Amar, R., Vayalapalli, S., & Drexler, K. (2009). Benefits of retention in methadone maintenance and chronic medical conditions as risk factors for premature death among older heroin addicts. Journal of Psychiatric Practice, 15(3), 227–234. doi:10.1097/01.pra.0000351884.83377.e2
   Google Scholar
• Farré, M., Mas, A., Torrens, M., Moreno, V., & Camí, J. (2002). Retention rate and illicit opioid use during methadone maintenance interventions: A meta-analysis. Drug and Alcohol Dependence, 65, 283–290. doi:10.1016/S0376-8716(0)00171-5
   Google Scholar
• Farwell, J. (2015, 1 May). ‘A system that doesn't exist’: Without methadone, patients rely on addiction treatment few Maine doctors prescribe. Bangor Daily News. Retrieved from http://bangordailynews.com/2015/05/01/health/a-system-that-doesnt-exist-without-methadone-patients-rely-on-addiction-treatment-few-maine-doctors-prescribe/
   Google Scholar
• Fischer, B., Rehm, J., Kim, G., & Kirst, M. (2005). Eyes wide shut?–A conceptual and empirical critique of methadone maintenance treatment. European Addiction Research, 11(1), 1–9. doi:10.1159/000081410
   Google Scholar
• Fraser, S., Pienaar, K., Dilkes-Frayne, E., Moore, D., Kokanovic, R., Treloar, C., & Dunlop, A. (2017). Addiction stigma and the biopolitics of liberal modernity: A qualitative analysis. International Journal of Drug Policy, in press.
   Google Scholar
• Fraser, S., & Valentine, K. (2008). Substance and substitution: Methadone subjects in liberal societies. New York: Palgrave Macmillan.
   Google Scholar
• Fraser, S., Valentine, K., Treloar, C., & Macmillan, K. (2007). Methadone maintenance treatment in New South Wales and Victoria: Takeaways, diversion and other key issues. Sydney, NSW, Australia: National Centre in HIV Social Research. Retrieved from http://nchsr.arts.unsw.edu.au/media/File/Methadone2007.pdf
   Google Scholar
• Freund, P. E. S., McGuire, M. B., & Podhurst, L. S. (2003). Health, illness, and the social body: A critical sociology. Upper Saddle River, NJ: Prentice Hall.
   Google Scholar
• Fugelstad, A., Stenbacka, M., Leifman, A., Nylander, M., & Thiblin, I. (2007). Methadone maintenance treatment: The balance between life-saving treatment and fatal poisonings. Addiction, 102(3), 406–412. doi:10.1111/j.1360-0443.2006.01714.x
   Google Scholar
• Galang, S. N. (2010, 16 December). No methadone clinic in Salem. The Salem News. Retrieved from http://www.salemnews.com/news/local_news/no-methadone-clinic-in-salem/article_5877ee38-e3bf-5238-8561-fe014987896a.html
   Google Scholar
• Genberg, B. L., Gillespie, M., Schuster, C. R., Johanson, C-E., Astemborski, J., Kirk, G. D., Vlahov, D., & Mehta, S. H. (2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addictive Behaviors, 38(12), 2868–2873. doi:10.1016/j.addbeh.2013.08.008
   Google Scholar
• Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. Englewood Cliffs, NJ: Prentice-Hall.
   Google Scholar
• Gowing, L., Farrell, M., & Bornemann, R. (2008). Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews, 16(2), Art. No. CD004145. doi:10.1002/14651858.CD004145.pub3
   Google Scholar
• Gryczynski, J., Mitchell, S. G., Jaffe, J. H., Kelly, S. M., Myers, C. P., O'Grady, K. E., Olsen, Y. K., & Schwartz, R. P. (2013). Retention in methadone and buprenorphine treatment among African Americans. Journal of Substance Abuse Treatment, 45(3), 287–292. doi:10.1016/j.jsat.2013.02.008
   Google Scholar
• Gryczynski, J., Mitchell, S. G., Jaffe, J. H., O'Grady, K. E., Olsen, Y. K., & Schwartz, R. P. (2014). Leaving buprenorphine treatment: Patients' reasons for cessation of care. Journal of Substance Abuse Treatment, 46(3), 356–361. doi:10.1016/j.jsat.2013.10.004
   Google Scholar
• Harris, J., & McElrath, K. (2012). Methadone as social control: Institutionalized stigma and the prospect of recovery. Qualitative Health Research, 22(6), 810–824. doi:10.1177/1049732311432718
   Google Scholar
• Harris, K. A., Arnsten, J. H., Joseph, H., Hecht, J., Marion, I., Juliana, P., & Gourevitch, M. N. (2006). A 5-year evaluation of a methadone medical maintenance program. Journal f Substance Abuse Treatment, 31, 433–438. doi:10.1016/j.jsat.2006.05.018
   Google Scholar
• Hartel, D. M., & Schoenbaum, E. E. (1998). Methadone treatment protects against HIV infection: Two decades of experience in the Bronx, New York City. Public Health Reports, 113(Suppl 1), 107–115.
   Google Scholar
• Hillhouse, M., Canamar, C. P., & Ling, W. (2013). Predictors of outcome after short-term stabilization with buprenorphine. Journal of Substance Abuse Treatment, 44(3), 336–342. doi:10.1016/j.jsat.2012.08.016
   Google Scholar
• Holt, M. (2007). Agency and dependency within treatment: Drug treatment clients negotiating methadone and antidepressants. Social Science and Medicine, 64, 1937–1947. doi:10.1016/j.socscimed.2007.01.011
   Google Scholar
• Jaffe, E. (2015). Not in my backyard: Neighbors protest methadone clinic. Komo News, 1 September. Retrieved: http://komonews.com/news/local/not-in-my-backyard-neighbors-protest-methadone-clinic
   Google Scholar
• Joseph, H., Stancliff, S., & Langrod, J. (2000). Methadone maintenance treatment (MMT): A review of historical and clinical issues. Mount Sinai Journal of Medicine, 67 (5,6), 347–364.
   Google Scholar
• Joseph, H., & Woods, J. S. (2006). In the service of patients: The legacy of Dr. Dole. Heroin Addiction and Related Clinical Problems, 8(4), 9–28.
   Google Scholar
• Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003). 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet, 361(9358), 662–668.
   Google Scholar
• Lind, B., Chen, S., Weatherburn, D., & Mattick, R. (2005). The effectiveness of methadone maintenance treatment in controlling crime: An Australian aggregate-level analysis. British Journal of Criminology, 45(2), 201–211. doi:10.1093/bjc/azh085
   Google Scholar
• Link, B. G., & Phelan, J. C. (2006). Stigma and its public health implications. Lancet, 367(9509), 528–529. doi:10.1016/S0140-6736(06)68184-1
   Google Scholar
• Liu, E., Liang, T., Shen, L., Zhong, H., Wag, B., Wu, Z., & Detels, R. (2009). Correlates of methadone client retention: A prospective cohort study in Guizhou province, China. International Journal of Drug Policy, 20, 304–308. doi:10.1016/j.drugpo.2008.09.004
   Google Scholar
• Lloyd, C. (2010). Sinning and sinned against: The stigmatisation of problem drug users. London: The UK Drug Policy Commission (UKDPC). Retrieved from http://www.ukdpc.org.uk/wp-content/uploads/Policy%20report%20-%20Sinning%20and%20sinned%20against_%20the%20stigmatisation%20of%20problem%20drug%20users.pdf
   Google Scholar
• Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. Journal of Addiction Medicine, 8(5), 315–326. doi:10.1097/ADM.0000000000000045
   Google Scholar
• Magura, S., & Rosenblum, A. (2001). Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. Mount Sinai Journal of Medicine, 68(1), 62–74. Retrieved from https://wmich.edu/sites/default/files/attachments/u372/2015/Leaving%20Methodone%20Treatment.pdf
   Google Scholar
• Mancino, M., Curran, G., Han, X., Allee, E., Humphreys, K., & Booth, B. M. (2010). Predictors of attrition from a national sample of methadone maintenance patients. American Journal of Drug and Alcohol Abuse, 36, 155–160. doi:10.3109/00952991003736389
   Google Scholar
• Marchand, K., & Oviedo-Joekes, E. (2017). Prioritizing the patient in patient-centered addictions treatment. Addiction, 112(3), 466–467. doi:10.1111/add.13680
   Google Scholar
• Matheson, C. (1998). Privacy and stigma in the pharmacy: Illicit drug users' perspectives and implications for pharmacy practice. Pharmaceutical Journal, 260, 639–641.
   Google Scholar
• Mill, J. E., Edwards, N., Jackson, R. C., MacLean, L., & Chaw-Kant, J. (2010). Stigmatization as a social control mechanism for persons living with HIV and AIDS. Qualitative Health Research, 20(11), 1469–1483. doi:10.1177/1049732310375436
   Google Scholar
• Mitchell, S. G., Gryczynski, J., Schwartz, R. P., Myers, C. P., O'Grady, K. E., Olsen, Y. K., & Jaffe, J. H. (2015). Changes in quality of life following buprenorphine treatment: Relationship with treatment retention and illicit opioid use. Journal of Psychoactive Drugs, 47(2), 149–157. doi:10.1080/02791072.2015.1014948
   Google Scholar
• Netherland, J., Botsko, M., Egan, J. E., Saxon, A. J., Cunningham, C. O., Finkelstein, R., Gourevitch, M. N., Renner, J. A., Sohler, N., Sullivan, L. E., Weiss, L., Fiellin, D. A., & the BHIVES Collaborative. (2009). Factors affecting willingness to provide buprenorphine treatment. Journal of Substance Abuse Treatment, 36(3), 244–251. doi:10.1016/j.jsat.2008.06.006
   Google Scholar
• Newman, R. G. (1976). Methadone maintenance: It ain't what it used to be. British Journal of Addiction, 71(2), 183–186.
   Google Scholar
• Nielsen, S., Hillhouse, M., Mooney, L., Ang, A., & Ling, W. (2015). Buprenorphine pharmacotherapy and behavioral treatment: Comparison of outcomes among prescription opioid users, heroin users and combination users. Journal of Substance Abuse Treatment, 48(1), 70–76. doi:10.1016/j.jsat.2014.06.006
   Google Scholar
• Nosyk, B., Marsh, D. C., Sun, H., Schecter, M. T., & Anis, A. H. (2010). Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996–2006. Journal of Substance Abuse Treatment, 39, 22–31. doi:10.1016/j.jsat.2010.03.008
   Google Scholar
• Opsal, T. D. (2011). Women disrupting a marginalized identity: Subverting the parolee identity through narrative. Journal of Contemporary Ethnography, 40(2), 135–167. doi:10.1177/0891241610384995
   Google Scholar
• Otiashvili, D., Piralishvili, G., Sikharulidze, Z., Kamkamidze, G., Poole, S., & Woody, G. E. (2013). Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—Outcomes of a randomized trial. Drug and Alcohol Dependence, 133(2), 376–382. doi:10.1016/j.drugalcdep.2013.06.024
   Google Scholar
• Pager, D. (2003). The mark of a criminal record. American Journal of Sociology, 108(5), 937–975. doi:10.1086/374403
   Web of Science ®Google Scholar
• Peddicord, A. N., Bush, C., & Cruze, C. (2015). A comparison of Suboxone and methadone in the treatment of opiate addiction. Journal of Addiction Research and Therapy, 6, 248. doi:10.4172/2155-6105.1000248
   Google Scholar
• Ponizovsky, A. M., & Grinshpoon, A. (2007). Quality of life among heroin users on buprenorphine versus methadone maintenance. American Journal of Drug and Alcohol Abuse, 33(5), 631–642. doi:10.1080/00952990701523698
   Google Scholar
• Porter, J. (1999). The street/treatment barrier: Treatment experiences of Puerto Rican injection drug users. Substance Use and Misuse, 34, 1951–1975. doi:10.3109/10826089909039434
   Google Scholar
• Reisinger, H. S., Schwartz, R. P., Mitchell, S. G., Peterson, J. A., Kelly, S. M., O'Grady, K. E., … Agar, M. H. (2009). Premature discharge from methadone treatment: Patient perspectives. Journal of Psychoactive Drugs, 41, 285–296.
   Google Scholar
• Rettig, R. A., & Yarmolinsky, A. eds. (1995). Federal regulation of methadone treatment. Committee on Federal Regulation of Methadone Treatment, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine. Washington, DC: National Academy Press. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK232113/
   Google Scholar
• Rosenblum, A., Cleland, C. M., Fong, C., Kayman, D. J., Tempalski, B., & Parrino, M. (2011). Distance traveled and cross-state commuting to opioid treatment programs in the United States. Journal of Environmental and Public Health, doi: 0.1155/2011/948789
   Google Scholar
• Saloner, B., Daubresse, M., & Caleb Alexander, G. (2017). Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Medical Care, Apr 13. doi:10.1097/MLR.0000000000000727 [ Epub ahead of print]
   Google Scholar
• Segall, J. (2011). Mass incarceration, ex-felon discrimination & black labor market disadvantage. University of Pennsylvania Journal of Law and Social Change, 14, 59–182. Retrieved from http://scholarship.law.upenn.edu/cgi/viewcontent.cgi?article=1109&context=jlasc
   Google Scholar
• Sheerin, I., Green, T., Sellman, D., Adamson, S., & Deering, D. (2004). Reduction in crime by drug users on a methadone maintenance therapy programme in New Zealand. New Zealand Medical Journal, 117(1190), 492–501, U795.
   Google Scholar
• Sigmon, S. (2015). The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry, 72(4), 395–396. doi:10.1001/jamapsychiatry.2014.2421
   Google Scholar
• Simoens, S., Matheson, C., Bond, C., Inkster, K., & Ludbrook, A. (2005). The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. British Journal of General Practice, 55(511), 139–146. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1463190/pdf/bjpg55-139.pdf
   Google Scholar
• Smye, V., Browne, A. J., Varcoe, C., & Josewski, V. (2011). Harm reduction, methadone maintenance treatment and the root causes of health and social inequities: An intersectional lens in the Canadian context. Harm Reduction Journal, 8, 17. doi:10.1186/1477-7517-8-17
   Google Scholar
• Sofastaii, M. (2016). Park Heights activists hold prayer meeting in protest to proposed methadone clinic. WMAR Baltimore, 30 March. Retrieved from: http://www.abc2news.com/news/region/baltimore-city/park-heights-activists-hold-prayer-meeting-in-protest-to-proposed-methadone-clinic
   Google Scholar
• Sontag, D. (2013, 16 November). Addiction treatment with a dark side. New York Times. Retrieved from http://www.nytimes.com/2013/11/17/health/in-demand-in-clinics-and-on-the-street-bupe-can-be-savior-or-menace.html
   Google Scholar
• State of Iowa. (2012). Probation agreement. Sixth Judicial District, Department of Correctional Services. Retrieved from http://iowacbc.org/wp-content/uploads/2012/04/ProbationAgreement.pdf
   Google Scholar
• Stein, B. D., Gordon, A.J., Dick, A. W., Burns, R. M., Pacula, R. L., Farmer, C. M., Leslie, D. L., & Sorbero, M. (2015). Supply of buprenorphine waivered physicians: The influence of state policies. Journal of Substance Abuse Treatment, 48(1), 104–111. doi:10.1016/j.jsat.2014.07.010
   Google Scholar
• Stone, E., & Fletcher, K. (2003). User views on supervised methadone consumption. Addiction Biology, 8, 45–48. doi:10.1080/1355621031000069873
   Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2015). Federal guidelines for opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from: http://store.samhsa.gov/shin/content/PEP15-FEDGUIDEOTP/PEP15-FEDGUIDEOTP.pdf
   Google Scholar
• Teesson, M., Ross, J., Darke, S., Lynskey, M., Ali, R., Ritter, A., & Cooke, R. (2006). One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence, 83, 174–180. doi:10.1016/j.drugalcdep.2005.11.009
   Google Scholar
• Teruya, C., Schwartz, R. P., Mitchell, S. G., Hasson, A. L., Thomas, C., Buoncristiani, S. H., Hser, Y.-I., Wiest, K., Cohen, A. J., Glick, N., Jacobs, P., McLaughlin, P., & Ling, W. (2014). Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the Starting Treatment with Agonist Replacement Therapies (START) study. Journal of Psychoactive Drugs, 46(5), 412–426. doi:10.1080/02791072.2014.921743
   Google Scholar
• Uggen, C., & Manza, J. (2006). Locked out: Felon disenfranchisement and American democracy. New York: Oxford University Press.
   Google Scholar
• United States Department of Health and Human Services. (2016). The opioid epidemic: By the numbers. Factsheet, 5 June. Retrieved from https://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf
   Google Scholar
• United States Probation and Pretrial, District of Idaho. (2014). Post-conviction supervision, standard conditions. Boise: United States Probation and Pretrial. Retrieved from http://www.id.uscourts.gov/probation/supervision/Standard_Conditions.cfm
   Google Scholar
• White, W. (2011). Life of clinical activism: An interview with Robert G. Newman, MD, MPH. Pioneer Interviews, Selected papers of William L. White. Retrieved from http://www.williamwhitepapers.com/pr/2011%20Dr.%20Robert%20Newman.pdf
   Google Scholar